Acuity Eye Group has purchased La Jolla Laser Vision & Eye Center for an undisclosed amount.
Vividion Therapeutics – a San Diego upstart that last year raised an $82 million financing round – has announced the hiring of a former Pfizer executive.
MEDICINE: Investor Interest Swirls around Companies
A crop of life sciences companies are rushing to combat the coronavirus outbreak, triggering big movements in their stocks and millions in grant funding.
Illumina recently made a major addition to its board: Scott Gottlieb, the former commissioner of the U.S. Food and Drug Administration.
The Bill & Melinda Gates Foundation has awarded $50 million to a division of Scripps Research to push forward potential therapies for tuberculosis and malaria.
The Association for Creatine Deficiencies was awarded a $450,000 grant to combat a trio of disorders that can cause intellectual delays.
San Diego company MeBe on Feb. 15 is slated to open a center catering to young adults and children with autism and special needs.
Conatus Pharmaceuticals has agreed to merge with another San Diego biotech, Histogen, it was announced Jan. 28.
Inovio Pharmaceuticals was recently awarded up to a $9 million grant to develop a vaccine against a strain of coronavirus that’s spreading in China and spurred screening at U.S. airports.
Illumina reported revenue of $953 million in fourth quarter revenue, a 10% year-over-year increase that also beat analyst expectations.
ResMed will pay $37.5 million to settle allegations that the company paid kickbacks to suppliers, sleep labs and other health care providers, the Department of Justice recently announced.
Tyra Biosciences, a Carlsbad company that wants to combat cancers that become drug-resistant, has raised a $50 million round.
Two DNA sequencing companies raised more than $140 million combined, Daré Bioscience inked a potential commercialization deal worth up to $310 million, and Human Longevity sold its cancer division for $37 million, and separately, acquired a company.
San Diego-based Neurocrine could buy the rights to yet another experimental epilepsy drug, per a recently announced agreement that could be worth up to $412 million.
Element Biosciences, another San Diego upstart that’s trying to make DNA technology more accessible, recently raised an $80.3 million round.